Lv7
4950 积分 2022-08-01 加入
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
12小时前
待确认
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
11天前
已关闭
Baricitinib in Patients with Refractory Rheumatoid Arthritis
12天前
已完结
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
14天前
已完结
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND
14天前
已关闭
POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS
14天前
已完结
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
17天前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
17天前
已完结
Anti‐Neuroinflammatory and Anti‐Inflammatory Effects of the NLRP3 Inhibitor NT‐0796 in Subjects with Parkinson's Disease
18天前
已完结
Trial of Prasinezumab in Early-Stage Parkinson’s Disease
20天前
已完结
皖公网安备34019202002308
